<p>中国广州，2025 年 12 月 22 日（GLOBE NEWSWIRE）——燃石医学（NASDAQ: BNR，以下简称 “ <strong>公司</strong>” 或 “ <strong>燃石</strong>”）是一家专注于在精准肿瘤学领域应用下一代测序（NGS）技术的公司，今天宣布在公司于今日召开的 2025 年年度股东大会上，所有提议的股东决议均已通过。具体而言，股东通过了以下决议：</p>
<ol>
<li>作为普通决议，批准安永华明会计师事务所担任公司截至 2025 年 12 月 31 日的审计师，并授权公司董事决定审计师的报酬；</li>
</ol>
<ol>
<li>作为普通决议，重新选举邓峰和许丽岑为公司董事；</li>
</ol>
<ol>
<li>作为普通决议，授权公司每位董事采取任何必要行动，以实施上述决议，具体由该董事自行决定。</li>
</ol>
<p><strong>关于燃石</strong></p>
<p>燃石医学（NASDAQ: BNR）的使命是通过科学守护生命，专注于在精准肿瘤学领域应用下一代测序（NGS）技术。其业务包括：i) 针对晚期癌症患者的基于 NGS 的治疗选择检测，以及 ii) 癌症早期检测，已从概念验证研发阶段进入临床验证阶段。</p>
<p>有关燃石的更多信息，请访问：ir.brbiotech.com。</p>
<p>联系方式：IR@brbiotech.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qUXdNQ00zTXpNME1qWXhJekl4T1RVeU5Uaz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qUXdNQ00zTXpNME1qWXhJekl4T1RVeU5Uaz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWU0NmYwYTctMGU2My00MDgzLTk4NjItNDllNTQ3ZTc1M2Q0LTEyMDY4MTItMjAyNS0xMi0yMy1lbg==/tiny/Burning-Rock-Biotech-Limited.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWU0NmYwYTctMGU2My00MDgzLTk4NjItNDllNTQ3ZTc1M2Q0LTEyMDY4MTItMjAyNS0xMi0yMy1lbg==/tiny/Burning-Rock-Biotech-Limited.png"/></p>

燃石医学

<p>燃石医学有限公司宣布，2025 年年度股东大会上的所有股东决议均已通过。决议包括确认安永华明会计师事务所为审计师，重新选举邓峰和许丽岑为董事，以及授权董事实施这些决议。燃石医学专注于精准肿瘤学中的下一代测序（NGS）技术</p>

<p>GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “ <strong>Company</strong>” or “ <strong>Burning Rock</strong>”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2025 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions:</p>
<div class="lb-trans"><p>中国广州，2025 年 12 月 22 日（GLOBE NEWSWIRE）——燃石医学（NASDAQ: BNR，以下简称 “ <strong>公司</strong>” 或 “ <strong>燃石</strong>”）是一家专注于在精准肿瘤学领域应用下一代测序（NGS）技术的公司，今天宣布在公司于今日召开的 2025 年年度股东大会上，所有提议的股东决议均已通过。具体而言，股东通过了以下决议：</p>
</div><ol>
<li>as an ordinary resolution, THAT the appointment of Ernst &amp; Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2025 be ratified and that the directors of the Company be authorized to determine the remuneration of the auditor;</li>
</ol>
<div class="lb-trans"><ol>
<li>作为普通决议，批准安永华明会计师事务所担任公司截至 2025 年 12 月 31 日的审计师，并授权公司董事决定审计师的报酬；</li>
</ol>
</div><ol>
<li>as an ordinary resolution, THAT Feng Deng and Licen Lisa Xu be re-elected as directors of the Company; and</li>
</ol>
<div class="lb-trans"><ol>
<li>作为普通决议，重新选举邓峰和许丽岑为公司董事；</li>
</ol>
</div><ol>
<li>as an ordinary resolution, THAT each of the directors of the Company be authorized to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.</li>
</ol>
<div class="lb-trans"><ol>
<li>作为普通决议，授权公司每位董事采取任何必要行动，以实施上述决议，具体由该董事自行决定。</li>
</ol>
</div><p><strong>About Burning Rock</strong></p>
<div class="lb-trans"><p><strong>关于燃石</strong></p>
</div><p>Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&amp;D into the clinical validation stage.</p>
<div class="lb-trans"><p>燃石医学（NASDAQ: BNR）的使命是通过科学守护生命，专注于在精准肿瘤学领域应用下一代测序（NGS）技术。其业务包括：i) 针对晚期癌症患者的基于 NGS 的治疗选择检测，以及 ii) 癌症早期检测，已从概念验证研发阶段进入临床验证阶段。</p>
</div><p>For more information about Burning Rock, please visit: ir.brbiotech.com.</p>
<div class="lb-trans"><p>有关燃石的更多信息，请访问：ir.brbiotech.com。</p>
</div><p>Contact: IR@brbiotech.com</p>
<div class="lb-trans"><p>联系方式：IR@brbiotech.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qUXdNQ00zTXpNME1qWXhJekl4T1RVeU5Uaz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjQwMCM3MzM0MjYxIzIxOTUyNTk="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWU0NmYwYTctMGU2My00MDgzLTk4NjItNDllNTQ3ZTc1M2Q0LTEyMDY4MTItMjAyNS0xMi0yMy1lbg==/tiny/Burning-Rock-Biotech-Limited.png" alt="" original-src="https://ml.globenewswire.com/media/ZWU0NmYwYTctMGU2My00MDgzLTk4NjItNDllNTQ3ZTc1M2Q0LTEyMDY4MTItMjAyNS0xMi0yMy1lbg==/tiny/Burning-Rock-Biotech-Limited.png"/></p>

燃石医学公布 2025 年度股东大会结果 | BNR 股票新闻